X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14903) 14903
Book Chapter (78) 78
Magazine Article (50) 50
Dissertation (49) 49
Newspaper Article (29) 29
Conference Proceeding (16) 16
Publication (15) 15
Book / eBook (6) 6
Government Document (6) 6
Web Resource (6) 6
Reference (4) 4
Book Review (2) 2
Trade Publication Article (2) 2
Newsletter (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (12510) 12510
humans (10013) 10013
female (7546) 7546
oncology (7346) 7346
breast cancer (6268) 6268
breast neoplasms - drug therapy (4938) 4938
chemotherapy (3678) 3678
cancer (3573) 3573
breast neoplasms - pathology (3290) 3290
middle aged (3148) 3148
antibodies, monoclonal, humanized (2971) 2971
receptor, erbb-2 - metabolism (2910) 2910
her2 (2752) 2752
antineoplastic agents - therapeutic use (2557) 2557
adult (2503) 2503
aged (2468) 2468
therapy (2312) 2312
breast neoplasms - metabolism (2087) 2087
animals (2005) 2005
antineoplastic combined chemotherapy protocols - therapeutic use (1961) 1961
antibodies, monoclonal - therapeutic use (1815) 1815
cell line, tumor (1690) 1690
treatment outcome (1679) 1679
breast neoplasms - genetics (1628) 1628
metastasis (1603) 1603
survival (1566) 1566
adjuvant chemotherapy (1552) 1552
care and treatment (1541) 1541
receptor, erbb-2 - genetics (1533) 1533
prognosis (1528) 1528
monoclonal-antibody (1446) 1446
skin and connective tissue diseases (1430) 1430
breast-cancer (1420) 1420
expression (1385) 1385
erbb-2 protein (1365) 1365
tumors (1339) 1339
mice (1288) 1288
research (1245) 1245
epidermal growth factor (1243) 1243
medicine & public health (1196) 1196
immunohistochemistry (1184) 1184
cancer therapies (1118) 1118
receptor, erbb-2 - antagonists & inhibitors (1116) 1116
analysis (1114) 1114
lapatinib (1106) 1106
pharmacology & pharmacy (1081) 1081
antineoplastic agents - pharmacology (1067) 1067
male (969) 969
aged, 80 and over (946) 946
disease-free survival (925) 925
paclitaxel (918) 918
neoplasm staging (906) 906
docetaxel (904) 904
antibodies, monoclonal - administration & dosage (894) 894
health aspects (891) 891
drug therapy (882) 882
breast neoplasms - mortality (879) 879
antibodies, monoclonal, humanized - therapeutic use (878) 878
efficacy (869) 869
gene amplification (866) 866
antineoplastic agents - adverse effects (864) 864
chemotherapy, adjuvant (855) 855
metastatic breast-cancer (853) 853
open-label (836) 836
receptor (812) 812
resistance (812) 812
monoclonal antibodies (808) 808
patients (804) 804
pertuzumab (790) 790
neoplasms (781) 781
phase-ii (780) 780
receptor, erbb-2 - analysis (774) 774
antibodies, monoclonal, humanized - administration & dosage (760) 760
antineoplastic agents (759) 759
neoadjuvant therapy (755) 755
retrospective studies (755) 755
growth-factor receptor (753) 753
neoplasm metastasis (749) 749
cardiotoxicity (742) 742
trial (741) 741
antibodies, monoclonal - pharmacology (706) 706
hematology, oncology and palliative medicine (704) 704
carcinoma (703) 703
clinical trials (702) 702
women (684) 684
antineoplastic agents - administration & dosage (682) 682
metastases (681) 681
proteins (680) 680
amplification (679) 679
cell biology (679) 679
breast neoplasms - therapy (677) 677
trastuzumab resistance (673) 673
herceptin (663) 663
antimitotic agents (655) 655
trastuzumab - therapeutic use (647) 647
gene expression (646) 646
safety (636) 636
trastuzumab - administration & dosage (633) 633
surgery (626) 626
growth (620) 620
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14167) 14167
Japanese (310) 310
French (304) 304
German (169) 169
Chinese (101) 101
Spanish (58) 58
Russian (49) 49
Polish (37) 37
Portuguese (32) 32
Italian (27) 27
Hungarian (18) 18
Czech (16) 16
Korean (16) 16
Turkish (9) 9
Dutch (8) 8
Danish (5) 5
Finnish (5) 5
Swedish (5) 5
Hebrew (4) 4
Norwegian (4) 4
Slovak (3) 3
Slovenian (3) 3
Bosnian (2) 2
Serbian (2) 2
Bulgarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Japanese Society of Gastroenterology, ISSN 0446-6586, 2017, Volume 114, Issue 1, pp. 59 - 68
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 973 - 15
Journal Article
Breast cancer (Tokyo, Japan), ISSN 1880-4233, 2015, Volume 22, Issue 2, pp. 101 - 116
Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imaging,... 
HER2-targeted therapy | Oncology | Adjuvant therapy | Neoadjuvant treatment | Medicine & Public Health | Pertuzumab | Surgery | Cancer Research | Lapatinib | Ado-trastuzumab emtansine | Bresat cancer | HER2-directed therapy | Surgical Oncology | Trastuzumab | 1ST-LINE TREATMENT | OPEN-LABEL | MONOCLONAL-ANTIBODY | TRASTUZUMAB RESISTANCE | ADJUVANT TRASTUZUMAB | OBSTETRICS & GYNECOLOGY | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | RANDOMIZED PHASE-II | TYROSINE KINASE INHIBITOR | LAPATINIB PLUS CAPECITABINE | NEOADJUVANT PERTUZUMAB | Breast Neoplasms - surgery | Small Molecule Libraries - pharmacology | Humans | Receptor, ErbB-2 - metabolism | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Maytansine - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Trastuzumab - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Maytansine - analogs & derivatives | Trastuzumab - administration & dosage | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Drug Resistance, Neoplasm - drug effects | Care and treatment | Chemotherapy | Breast cancer | Biological products | Cancer
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2767 - 2777
Aims We conducted population pharmacokinetic (PopPK) and exposure–response analyses for trastuzumab emtansine (T‐DM1), to assess the need for T‐DM1 dose... 
population pharmacokinetics (PopPK) | exposure–response (E‐R) | trastuzumab emtansine (T‐DM1) | metastatic breast cancer | exposure–response (E-R) | trastuzumab emtansine (T-DM1) | exposure-response (E-R) | SOLID TUMORS | MODELS | CAUSAL INFERENCE | PHARMACOLOGY | PHARMACOLOGY & PHARMACY | GUIDE | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Agents, Immunological - pharmacokinetics | Area Under Curve | Trastuzumab - pharmacokinetics | Humans | Receptor, ErbB-2 - metabolism | Ado-Trastuzumab Emtansine | Metabolic Clearance Rate | Trastuzumab - blood | Antineoplastic Agents, Immunological - blood | Breast Neoplasms - enzymology | Tubulin Modulators - administration & dosage | Female | Receptor, ErbB-2 - antagonists & inhibitors | Maytansine - blood | Tubulin Modulators - blood | Maytansine - adverse effects | Tubulin Modulators - adverse effects | Risk Assessment | Maytansine - analogs & derivatives | Tubulin Modulators - pharmacokinetics | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Logistic Models | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Maytansine - administration & dosage | Models, Biological | Maytansine - pharmacokinetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Infusions, Intravenous | Nonlinear Dynamics | Pharmacokinetic Dynamic Relationships
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 2018, Volume 24, Issue 5, pp. 1082 - 1089
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 2, pp. 122 - 131
Journal Article